Insulin Aspart Dosing in Acute Renal Failure
In patients with acute renal failure (AKI), reduce the starting insulin aspart dose to 0.2-0.3 units/kg/day (or lower at 0.15-0.25 units/kg/day in elderly or those with poor oral intake), target blood glucose of 140-180 mg/dL, use the insulin-sensitive correction scale, and increase monitoring frequency due to significantly elevated hypoglycemia risk. 1, 2
Dosing Adjustments
Initial Dose Reduction
- Start at 0.2-0.3 units/kg/day for patients with GFR <60 mL/min or AKI 1
- Further reduce to 0.15-0.25 units/kg/day if patient is elderly, has poor caloric intake, or is at high hypoglycemia risk 3
- Distribute as 50% basal insulin and 50% nutritional (prandial) insulin 1
The rationale: Insulin is metabolized by the kidney, and renal impairment dramatically increases hypoglycemia risk. Studies show hypoglycemia occurs in 76% of critically ill patients with renal failure versus 35% with normal function, with severe hypoglycemia (<40 mg/dL) in 29% versus 0% 2. The FDA label confirms no significant pharmacokinetic changes with renal impairment 4, but clinical outcomes demonstrate substantially increased hypoglycemia risk 2.
Prandial Insulin (Insulin Aspart) Dosing
- Give rapid-acting insulin aspart in three equally divided doses before each meal 1
- Hold prandial insulin if patient cannot eat 1
- If not eating: give insulin aspart every 4-6 hours using the insulin-sensitive column for corrections 1
Glycemic Targets - Critical Difference
Target glucose 140-180 mg/dL (7.8-10 mmol/L) in AKI patients - NOT the tighter 110-149 mg/dL used in other critically ill patients 2. The 2024 ESPEN guidelines provide Grade A evidence that tight glucose control (80-110 mg/dL) must not be pursued due to unacceptable hypoglycemia risk 2.
This represents a deliberate loosening of targets compared to standard critical care, recognizing that renal dysfunction fundamentally alters insulin metabolism and glucose regulation 2.
Correction Insulin Scale
Use the insulin-sensitive column for all AKI patients 1:
| Blood Glucose (mg/dL) | Insulin-Sensitive Dose (units) |
|---|---|
| 141-180 | 2 |
| 181-220 | 4 |
| 221-260 | 6 |
| 261-300 | 8 |
| 301-350 | 10 |
| 351-400 | 12 |
| ≥400 | 14 |
Give half the supplemental dose at bedtime 1. This conservative approach is essential because AKI patients demonstrate increased glycemic variability and unpredictable insulin responses 2.
Monitoring Requirements
- Increase frequency of blood glucose monitoring beyond standard protocols 1, 2
- Monitor for hypoglycemia signs, though these may be blunted 1
- Adjust doses based on bedside glucose measurements 1
- Reassess insulin requirements with any change in renal function 5, 6
Critical Pitfalls to Avoid
Never use standard weight-based dosing (0.4-0.5 units/kg/day) - this is for patients with normal renal function and will cause severe hypoglycemia in AKI 1
Do not use the "usual" or "insulin-resistant" correction columns - AKI patients require the sensitive scale regardless of prior insulin requirements 1
Avoid sliding scale insulin as sole therapy - use scheduled basal-bolus regimens with appropriate dose reductions 1, 7
Do not maintain tight glycemic control targets - the 140-180 mg/dL range is evidence-based for AKI, not a compromise 2
Insulin requirements may decrease further as AKI progresses - continuous reassessment is mandatory 5, 6
Special Considerations
Insulin aspart pharmacokinetics are not significantly altered by renal impairment per FDA labeling and research 4, 8, but the clinical risk of hypoglycemia is dramatically increased due to decreased insulin clearance, altered counter-regulatory responses, and unpredictable glucose metabolism 2. This disconnect between pharmacokinetics and clinical outcomes necessitates the conservative dosing approach.
For patients on dialysis, additional considerations apply, but the question specifically addresses acute renal failure, not chronic dialysis management 9.